Ingrezza for Tardive Dyskinesia: Its Safety, Efficacy, and Implication

JUNE 06, 2017
Kevin Kunzmann

Laxman Bahroo, DO, director of the Botulinum Toxin Clinic and associate professor of Neurology at Georgetown University Hospital, took time out of the 21st International Congress of Parkinson's Disease and Movement Disorders to discuss Ingrezza, the first and only treatment approved for Tardive Dyskinesia.

Copyright© MD Magazine 2006-2020 Intellisphere, LLC. All Rights Reserved.